FACTORS INFLUENCING ORPHAN DRUG NET PRICES IN THE EU4 AND US - INSIGHTS FROM PAYERS

被引：0
|
作者：
Ergin, Y. [1 ]
Rex, M. [1 ]
Yadav, V [1 ]
Hasson, O. [1 ]
Haney, E. [1 ]
机构：
[1] Inbeeo Ltd, London, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR102
引用
收藏
页码：S272 / S272
页数：1
相关论文
共 14 条
  • [1] COMPARATIVE ANALYSIS OF LAUNCH PRICES FOR ORPHAN DRUGS IN THE US AND EU4
    Mietus, Z.
    VALUE IN HEALTH, 2024, 27 (06) : S152 - S153
  • [2] EVIDENCE REQUIREMENTS IN THE REGULATORY AND REIMBURSEMENT PROCESSES OF DIGITAL THERAPEUTICS: INSIGHTS FROM THE US, EU4 AND UK
    Morga, A.
    Chettiath, A.
    Saxena, A.
    VALUE IN HEALTH, 2022, 25 (01) : S196 - S196
  • [3] Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry
    Bruyaka, Olga
    Zeitzmann, Hanko K.
    Chalamon, Isabelle
    Wokutch, Richard E.
    Thakur, Pooja
    JOURNAL OF BUSINESS ETHICS, 2013, 117 (01) : 45 - 65
  • [4] Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry
    Olga Bruyaka
    Hanko K. Zeitzmann
    Isabelle Chalamon
    Richard E. Wokutch
    Pooja Thakur
    Journal of Business Ethics, 2013, 117 : 45 - 65
  • [5] UNDERSTANDING TRENDS IN LAUNCH PRICES ACROSS CANADA, EU4, UK AND THE US FOR HIGH-REVENUE DRUGS
    Das, M.
    Lee, K.
    Ng-Haing, J.
    Shan, S.
    VALUE IN HEALTH, 2024, 27 (06) : S108 - S108
  • [6] ASSESSING THE INFLUENCE OF THE ORPHAN DRUG STATUS ON MEDICINE PRICES IN THE EU4+UK
    Perez, A.
    Gas, N.
    Rives, V
    Parlato, G.
    Gaddam, K.
    Vialard, L.
    VALUE IN HEALTH, 2022, 25 (12) : S257 - S257
  • [7] ORPHAN DRUG PRICING: DIFFERENCES BETWEEN US AND EUROPE, INFLUENCING FACTORS AND FUTURE DIRECTIONS
    Chen, X.
    Weisse, S.
    VALUE IN HEALTH, 2017, 20 (05) : A229 - A229
  • [8] ORPHAN DRUG DESIGNATION: A COMPARISON OF POLICIES, PROCESSES AND RESULTS FROM THE US AND THE EU
    Shields, G. E.
    Neves, Arranhado A. C.
    Bajpai, S. K.
    VALUE IN HEALTH, 2015, 18 (03) : A305 - A305
  • [9] KEY HTA LEARNINGS FROM APPROVED GENE THERAPIES ACROSS THE EU4, ENGLAND, AND THE US
    Kiritharan, P.
    Sanseau, J.
    Johns, O.
    VALUE IN HEALTH, 2023, 26 (12) : S370 - S370
  • [10] CHANGING LANDSCAPE OF ORPHAN DRUG REIMBURSEMENT - EVIDENCE FROM EU-4 AND ENGLAND
    Foxon, G.
    Tokarska, J.
    Debevec, D.
    Guillot, M.
    Lizan, L.
    Prada, M.
    Vollmer, L.
    VALUE IN HEALTH, 2022, 25 (12) : S235 - S235
12